OPK OPKO Health Inc.

OPKO Health to Participate in BTIG Virtual Biotechnology Conference

OPKO Health to Participate in BTIG Virtual Biotechnology Conference

MIAMI, Aug. 05, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 9:00 a.m. Eastern time.  In addition, management will be hosting one-on-one meetings with investors via organized conference calls.

A live webcast of the fireside chat can be accessed from the investor section of OPKO’s website . A replay of the event will be available for a period of time.

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit .

Contacts:

LHA Investor Relations

Yvonne Briggs, 310-691-7100



or

Bruce Voss, 310-691-7100

EN
05/08/2020

Underlying

OPKOPKO Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OPKO Health Inc.

 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health to Participate in the Jefferies Biotech on the Beach Summi...

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...

February 27, 2026 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...

February 26, 2026 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health to Report Fourth Quarter 2025 Financial Results on Februar...

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...

February 12, 2026 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...

February 4, 2026 1 EN
 PRESS RELEASE
Free
OPK OPKO Health In...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare C...

OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors sectio...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch